| Citation: |
XIA Limin, HUO Yongping, MA Xiangmin, CHEN Shihao. Diagnostic Value of Combined Detection of Serum AIF-1, GDF15, and DCLK1 in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(12): 1028-1033. DOI: 10.3971/j.issn.1000-8578.2024.24.0273
|
To explore the diagnostic value of the combined detection of serum allograft inflammatory factor-1 (AIF-1), growth differentiation factor-15 (GDF15), and doublecortin-like kinase 1 (DCLK1) in breast cancer.
A total of 114 female breast cancer patients (breast cancer group) and 114 female volunteers (control group) who underwent physical examination were selected. Enzyme-Linked immunosorbent assay was applied to detect serum levels of AIF-1, GDF15, and DCLK1. Multivariate Logistic regression was used to analyze the risk factors affecting breast cancer. ROC curve was used to analyze the diagnostic value of serum AIF-1, GDF15, DCLK1 levels in breast cancer.
The serum levels of AIF-1, GDF15, and DCLK1 in the breast cancer group were obviously higher than those of the control group (P<0.05). The expression levels of serum AIF-1, GDF15, and DCLK1 were significantly elevated in breast cancer patients with stage Ⅲ-Ⅳ, moderate and poor differentiation, lymph-node metastasis, and Ki-67 positive (P<0.05). Serum AIF-1, GDF15, and DCLK1 were risk factors for breast cancer, and the areas under the curve (AUC) for single and combined diagnosis of breast cancer for all three were 0.834, 0.753, 0.861, and 0.930, respectively. Additionally, the combined diagnosis AUC values were significantly higher than those assessed alone (Zcombination-AIF-1=3.479, Zcombination-GDF15=5.147, and Zcombination-DCLK1=3.121; all P<0.05).
In breast cancer patients, the serum AIF-1, GDF15, and DCLK1 levels increase. They are risk factors for breast cancer, and the combined diagnosis of the three is more effective.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Zannetti A. Breast Cancer: From Pathophysiology to Novel Therapeutic Approaches 2.0[J]. Int J Mol Sci, 2023, 24(3): 2542-2553. doi: 10.3390/ijms24032542
|
| [2] |
Ben-Dror J, Shalamov M, Sonnenblick A. The History of Early Breast Cancer Treatment[J]. Genes (Basel), 2022, 13(6): 960-964. doi: 10.3390/genes13060960
|
| [3] |
Lee Y, Ni J, Beretov J, et al. Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis[J]. Mol Cancer, 2023, 22(1): 33-39. doi: 10.1186/s12943-023-01741-x
|
| [4] |
Guijarro LG, Cano-Martínez D, Toledo-Lobo MV, et al. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity[J]. Biomedicines, 2022, 10(3): 727-735. doi: 10.3390/biomedicines10030727
|
| [5] |
Siddiqui JA, Pothuraju R, Khan P, et al. Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia[J]. Cytokine Growth Factor Rev, 2022, 64(1): 71-83.
|
| [6] |
Chhetri D, Vengadassalapathy S, Venkadassalapathy S, et al. Pleiotropic effects of DCLK1 in cancer and cancer stem cells[J]. Front Mol Biosci, 2022, 9: 965730-965738. doi: 10.3389/fmolb.2022.965730
|
| [7] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019, 29(8): 609-680. [The Society of Breast Cancer of China Anti-CancerAssociation. Chinese Cancer Association Guidelines for Breast Cancer Diagnosis and Treatment(2019 Edition)[J]. Zhongguo Ai Zeng Za Zhi, 2019, 29(8): 609-680.]
The Society of Breast Cancer of China Anti-CancerAssociation. Chinese Cancer Association Guidelines for Breast Cancer Diagnosis and Treatment(2019 Edition)[J]. Zhongguo Ai Zeng Za Zhi, 2019, 29(8): 609-680.
|
| [8] |
姜斌, 徐浩, 张宇聪, 等. 血清前列腺特异性抗原在乳腺癌中表达水平的变化及诊断价值的Meta分析[J]. 中华实验外科杂志, 2020, 37(7): 1212-1214. [Jiang B, Xu Hao, Zhang YC, et al. A Meta analysis of expression level change and diagnosis value of serum prostate specificantigen in patients with breast cancer[J]. Zhonghua Shi Yan Wai Ke Za Zhi, 2020, 37(7): 1212-1214.] doi: 10.3760/cma.j.cn421213-20200709-00498
Jiang B, Xu Hao, Zhang YC, et al. A Meta analysis of expression level change and diagnosis value of serum prostate specificantigen in patients with breast cancer[J]. Zhonghua Shi Yan Wai Ke Za Zhi, 2020, 37(7): 1212-1214. doi: 10.3760/cma.j.cn421213-20200709-00498
|
| [9] |
Houghton SC, Hankinson SE. Cancer Progress and Priorities: Breast Cancer[J]. Cancer Epidemiol Biomarkers Prev, 2021, 30(5): 822-844. doi: 10.1158/1055-9965.EPI-20-1193
|
| [10] |
Piotrowska K, Słuczanowska-Głabowska S, Kurzawski M, et al. Over-Expression of Allograft Inflammatory Factor-1 (AIF-1) in Patients with Rheumatoid Arthritis[J]. Biomolecules, 2020, 10(7): 1064-1071. doi: 10.3390/biom10071064
|
| [11] |
Vizioli J, Verri T, Pagliara P. Allograft Inflammatory Factor-1 in Metazoans: Focus on Invertebrates[J]. Biology (Basel), 2020, 9(11): 355-361.
|
| [12] |
Wang L, Zhao X, Zheng H, et al. AIF-1, a potential biomarker of aggressive tumor behavior in patients with non-small cell lung cancer[J]. PLoS One, 2022, 17(12): e0279211. doi: 10.1371/journal.pone.0279211
|
| [13] |
Sikora M, Kopeć B, Piotrowska K, et al. Role of allograft inflammatory factor-1 in pathogenesis of diseases[J]. Immunol Lett, 2020, 218: 1-4. doi: 10.1016/j.imlet.2019.12.002
|
| [14] |
Ma Y, Du J, Chen M, et al. Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights[J]. Front Immunol, 2023, 14: 1219652. doi: 10.3389/fimmu.2023.1219652
|
| [15] |
Baek SJ, Eling T. Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases[J]. Pharmacol Ther, 2019, 198: 46-58. doi: 10.1016/j.pharmthera.2019.02.008
|
| [16] |
Ahmed DS, Isnard S, Lin J, et al. GDF15/GFRAL Pathway as a Metabolic Signature for Cachexia in Patients with Cancer[J]. J Cancer, 2021, 12(4): 1125-1132. doi: 10.7150/jca.50376
|
| [17] |
Huang JY, Wang YY, Lo S, et al. Visfatin Mediates Malignant Behaviors through Adipose-Derived Stem Cells Intermediary in Breast Cancer[J]. Cancers (Basel), 2019, 12(1): 29-35. doi: 10.3390/cancers12010029
|
| [18] |
Zhao X, Liu X, Hu S, et al. GDF15 Contributes to Radioresistance by Mediating the EMT and Stemness of Breast Cancer Cells[J]. Int J Mol Sci, 2022, 23(18): 10911-10918. doi: 10.3390/ijms231810911
|
| [19] |
Huang Z, Shen S, Han X, et al. Macrophage DCLK1 promotes atherosclerosis via binding to IKKβ and inducing inflammatory responses[J]. EMBO Mol Med, 2023, 15(5): 17198-17203. doi: 10.15252/emmm.202217198
|
| [20] |
Venkat A, Watterson G, Byrne DP, et al. Mechanistic and evolutionary insights into isoform-specific 'supercharging' in DCLK family kinases[J]. Elife, 2023, 12: RP87958. doi: 10.7554/eLife.87958
|
| [21] |
Gzil A, Szylberg Ł, Jaworski D, et al. The Essential Role of DCLK1 in Pathogenesis, Diagnostic Procedures and Prognostic Stratification of Colorectal Cancer[J]. Anticancer Res, 2019, 39(6): 2689-2697. doi: 10.21873/anticanres.13394
|
| [1] | LU Hui, XIE Zhengyuan. Research Progress in Noninvasive Early Diagnosis of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 75-80. DOI: 10.3971/j.issn.1000-8578.2023.22.0642 |
| [2] | YAN Xiaolu, GAO Zhe, LI Qingxia. Clinical Significance of Serum Levels of IGF-1 and CA153 in Patients with Recurrence of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(05): 481-482. DOI: 10.3971/j.issn.1000-8578.2015.05.013 |
| [3] | Fu Weijin, Mi Hua, Liu Deyun, Yan Haibiao, Huang Weihua, Mo Zengnan. Diagnosis and Treatment of Adrenal Schwannoma[J]. Cancer Research on Prevention and Treatment, 2013, 40(01): 87-89. DOI: 10.3971/j.issn.1000-8578.2013.01.022 |
| [4] | CHENG-Bo, ZHANG Ai-min, MA Fu-jun, LI Shu-guang, HU Hai-long, LIU Li-wei, HAN Ru-fa. Diagnosis and Treatment of Renal Pelvis Carcinoma (Report of 92 Cases)[J]. Cancer Research on Prevention and Treatment, 2011, 38(08): 933-936. DOI: 10.3971/j.issn.1000-8578.2011.08.020 |
| [5] | QU Hong-yan, PANG DA, XUE Ying-wei, et al, . Diagnosis and treatment of spleen tumor[J]. Cancer Research on Prevention and Treatment, 2002, 29(04): 316-316. DOI: 10.3971/j.issn.1000-8578.3303 |
| [6] | HUANG ZHao-sui, WANG Yi-ming, HUANG CHun-hong, et al, . The application of TSGF test in the diagnosis of carcinosis[J]. Cancer Research on Prevention and Treatment, 2002, 29(03): 215-216. DOI: 10.3971/j.issn.1000-8578.1552 |
| [7] | CAI Xiao-qing, LI Wen-guang. The diagnosis and treatment of the bladder mixed tumor[J]. Cancer Research on Prevention and Treatment, 2002, 29(02): 133-134. DOI: 10.3971/j.issn.1000-8578.941 |
| [8] | CT in Diagnosis of Maxillary Sinus Neoplasm[J]. Cancer Research on Prevention and Treatment, 1999, 26(6): 455-456. |
| [9] | Lu Guangsheng, Dou Kefeng, Li Kaizhong, . Diagnosis and Surgical Treatment Extrahepatic of Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 1999, 26(2): 127-128. |
| [10] | Wang Zi-Bin, . Clinical Radiological Diagnosis of Pulmonary Carcinoma in Special Types[J]. Cancer Research on Prevention and Treatment, 1995, 22(4): 241-244. |
Figures(1) / Tables(4)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: